Table 2. Incidence and relative risk of all-grade QTc interval prolongation associated with VEGFR TKIs stratified by drug.
| |
|
|
Incidence |
|
|
|
|---|---|---|---|---|---|---|
| Type of drug | Number of studies | Number of events/sample size TKI; Control | VEGFR TKIs % (95% CI) | Control % (95% CI) | Relative risk (95% CI) | P-value |
| Overall |
18 |
165/3737; 7/2811 |
4.9 (2.9–7.9) |
0.9 (0.5–1.5) |
8.66 (4.92–15.2) |
<0.001 |
| Vandetanib |
13 |
154/2432; 7/1772 |
8.0 (5.0–12.7) |
1.2 (0.6–2.2) |
9.63 (5.14–18.0) |
<0.001 |
| 100 mg |
7 |
25/1141; 4/1155 |
3.6 (1.6–7.5) |
1.5 (0.6–3.3) |
4.83 (1.94–12.0) |
0.001 |
| 300 mg |
11 |
129/1291; 7/809 |
12.2 (8.3–17.7) |
1.5 (0.8–2.8) |
10.6 (5.31–21.2) |
<0.001 |
| Sunitinib |
2 |
8/455; 0/455 |
2.0 (1.0–3.8) |
0.2 (0.0–1.6) |
9.01 (1.15–70.7) |
0.04 |
| Pazopanib |
2 |
2/536; 0/268 |
0.4 (0.1–1.5) |
0.4 (0.0–2.6) |
1.51 (0.16–14.4) |
0.72 |
| Axitiniba | 1 | 1/314; 0/316 | 0.3 (0.04–2.2) | 0.2 (0.0–2.4) | 3.02 (0.12–73.8) | 0.50 |
Abbreviations: CI=confidence interval; TKI=tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor receptor.
a
Only one trial is available, and we thus did not conduct a meta-analysis for axitinib.